MiRXES Sees China as Crucial Market for Growth
ByAinvest
Friday, May 23, 2025 12:20 am ET1min read
MIR--
The partnership will operate under the unified brand VRR Life Sciences, a Unicon Company, and is a significant step in Unicon's broader vision of building an integrated global platform for validation and regulatory excellence. The collaboration combines Unicon's strong U.S. market presence with VRR's extensive CSV expertise and offshore delivery model, aiming to provide enhanced value through speed, cost-efficiency, and quality assurance.
Ravi Kollipara, CEO of Unicon Pharma, stated, "Our clients are operating in a time of regulatory transformation, with increasing expectations around data integrity, digital systems, and global compliance. With VRR Life Sciences joining our platform, we are not only expanding our technical depth—we are reinforcing our ability to deliver high-quality results at scale."
Gireesh T., CEO of VRR Life Sciences, commented, "Joining with Unicon allows us to bring our proven methods to new markets while aligning with a partner who shares our values and standards. It's an important step forward for our team and the clients we'll serve together."
VRR Life Sciences, a Unicon Company, will focus on enterprise-level CSV projects, data integrity remediation, and IT compliance initiatives, helping life sciences organizations reduce risk, enhance quality, and accelerate delivery across the development lifecycle.
This partnership follows Unicon's 2024 collaboration with CORE to enhance CQV services and aligns with its broader vision of building an integrated global platform for validation and regulatory excellence.
For more information, visit:
- Unicon Pharma Inc: http://www.uniconpharma.com
- VRR Life Sciences: http://www.vrrlifesciences.com
[1] https://www.morningstar.com/news/pr-newswire/20250521ny54231/unicon-pharma-announces-strategic-partnership-with-vrr-life-sciences-to-expand-global-csv-capabilities-and-support-digital-transformation-in-life-sciences
VRAR--
MiRXES, a Singapore-based life sciences company, plans to expand its presence in China, which it sees as an important market. The company has already established partnerships with Chinese hospitals and plans to increase its sales and marketing efforts in the country. MiRXES aims to tap into China's growing demand for cancer diagnostics and treatment, and is optimistic about the market's potential for growth.
SOUTH PLAINFIELD, N.J., May 21, 2025 — Unicon Pharma, a leading provider of compliance, validation, and workforce solutions for the life sciences industry, has announced a strategic partnership with VRR Life Sciences. This collaboration aims to enhance Unicon's global capabilities in Computer System Validation (CSV) and support digital transformation in the life sciences sector.The partnership will operate under the unified brand VRR Life Sciences, a Unicon Company, and is a significant step in Unicon's broader vision of building an integrated global platform for validation and regulatory excellence. The collaboration combines Unicon's strong U.S. market presence with VRR's extensive CSV expertise and offshore delivery model, aiming to provide enhanced value through speed, cost-efficiency, and quality assurance.
Ravi Kollipara, CEO of Unicon Pharma, stated, "Our clients are operating in a time of regulatory transformation, with increasing expectations around data integrity, digital systems, and global compliance. With VRR Life Sciences joining our platform, we are not only expanding our technical depth—we are reinforcing our ability to deliver high-quality results at scale."
Gireesh T., CEO of VRR Life Sciences, commented, "Joining with Unicon allows us to bring our proven methods to new markets while aligning with a partner who shares our values and standards. It's an important step forward for our team and the clients we'll serve together."
VRR Life Sciences, a Unicon Company, will focus on enterprise-level CSV projects, data integrity remediation, and IT compliance initiatives, helping life sciences organizations reduce risk, enhance quality, and accelerate delivery across the development lifecycle.
This partnership follows Unicon's 2024 collaboration with CORE to enhance CQV services and aligns with its broader vision of building an integrated global platform for validation and regulatory excellence.
For more information, visit:
- Unicon Pharma Inc: http://www.uniconpharma.com
- VRR Life Sciences: http://www.vrrlifesciences.com
[1] https://www.morningstar.com/news/pr-newswire/20250521ny54231/unicon-pharma-announces-strategic-partnership-with-vrr-life-sciences-to-expand-global-csv-capabilities-and-support-digital-transformation-in-life-sciences
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet